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Background: Tumor necrosis factor-alpha (TNF-α) is an important inflammatory cytokine that may play a role in
controlling the progression of prostate cancer. Two common polymorphisms in the TNF-α gene, −308G/A and
−238C/T, have been suggested to alter the risk for prostate cancer, but the results have been inconclusive so far. In
order to obtain a better understanding of the effects of these two polymorphisms on prostate cancer risk, all available
studies were considered in a meta-analysis.
Methods: We conducted a comprehensive literature search in the Cochrane Library, PubMed, EMBASE, Chinese
Biomedical Literature database (CBM), and the China National Knowledge Infrastructure (CNKI). The associations were
evaluated by calculating the pooled odds ratio (OR) with 95% confidence interval (95% CI).
Results: In this meta-analysis, we included 14 studies with 5,757 patients and 6,137 control subjects for the TNF-α-308G/A
polymorphism and 1,967 patients and 2,004 control subjects for the TNF-α-238C/T polymorphism. A significantly increased
prostate cancer risk was found to be associated with the TNF-α-308C/T polymorphism in studies with healthy volunteers
(AA + AG vs. GG: OR = 1.531, 95% CI = 1.093–2.145; P = 0.013; AG vs. GG: OR = 1.477, 95% CI = 1.047–2.085; P = 0.026). No
significant association was found between the TNF-α-238G/A polymorphism and prostate cancer risk in the overall or
subgroup analyses. There was no risk of publication bias in this meta-analysis.
Conclusions: Our results suggest that while the TNF-α-238G/A polymorphism may not be associated with prostate
cancer the TNF-α-308C/T polymorphism may significantly contribute to prostate cancer susceptibility in healthy
volunteers.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1629288120116301
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Prostate cancer is the most common malignant tumour
of the male reproductive system in the Western hemi-
sphere. Approximately 238,590 new cases and 29,270
deaths of prostate cancer are reported annually [1].
Therefore, it is critically important to clarify the mech-
anism of its carcinogenesis, so that prostate cancer can
be detected at an early stage. Polygenic and external en-
vironmental factors are known or suspected to be risk* Correspondence: qinxue919@126.com; lis8858@126.com
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unless otherwise stated.factors for prostate cancer [2-4]. Specifically, genetic fac-
tors may contribute as much as 42% to the risk of prostate
cancer [5]. Recently, cytokine genetic polymorphisms were
found to be related associated with increased inflamma-
tion, increased cytokine production, and possibly in-
creased prostate cancer risk [6].
Tumour necrosis factor-alpha (TNF-α) is a mediator
of the inflammatory process that is secreted by mono-
cytes, macrophages, neutrophils, T cells, and NK cells
after stimulation. TNF-α is a pro-inflammatory molecule
that may play an important role in the development of
the immune response [7,8] and affect the progression of
prostate cancer [9]. The TNF-α gene is located in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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some 6p21.3. In recent years, several common single nu-
cleotide polymorphisms (SNPs) have been identified in
the TNF-α promoter regions, which can regulate the
expression level of TNF-α, such as TNF-α-308G/A
(rs1800629) and TNF-α-238C/T (rs361525) [10,11].
TNF-α 308G/A is a G to A transition at nucleotide pos-
ition 308 in the promoter region of the gene, and TNF-
α-238G/A is a G to A transition at nucleotide position
238 in the promoter region of the gene. Previous data
have shown that polymorphisms of TNF-α at positions
308 and 238 (TNF2 and TNFA alleles, respectively) are
associated with increased release of TNF-α [6,12,13].
Therefore, TNF-α polymorphism may be related to pros-
tate cancer risk. Thus, it is biologically reasonable to
hypothesize a potential relationship between TNF-α
polymorphisms and prostate cancer risk.
A number of studies have reported the association be-
tween prostate cancer risk and TNF-α promoter poly-
morphisms –308G/A and/ or –238G/A polymorphisms,
but the results are controversial [14-16]. A single study
may not have sufficient power to completely demon-
strate this complicated genetic relationship because of
relatively small sample sizes, which have low statistical
power. Larger studies could overcome these disadvan-
tages. With respect to the TNF-α-308G/A polymorph-
ism, Wang et al. [17] conducted a meta-analysis in 2011
and found that this polymorphism was not associated
with susceptibility to prostate cancer. However, that
meta-analysis only included six eligible studies and sev-
eral new studies with more data have been published
since 2011; thus, that meta-analysis may not be compre-
hensive and may cause some bias to the final result. To
the best of our knowledge, no meta-analyses investigat-
ing the TNF-α-238G/A polymorphism have ever been
published. Therefore, to generate a more valuable con-
clusion on the association between TNF-α polymor-
phisms and prostate cancer risk, we performed a meta-
analysis of all eligible case–control studies investigating
the association between the –308G/A and -238G/A




We conducted a comprehensive literature search in the
Cochrane Library, PubMed, EMBASE, Chinese Biomedical
Literature database (CBM), and the China National
Knowledge Infrastructure (CNKI) using the search terms
“prostate cancer OR prostate carcinoma OR PCa”,
“polymorphism or variant OR mutation OR genotype”
and “Tumour Necrosis Factor-alpha OR TNF OR TNF-α”
and various combinations of these terms. All the articles
were updated on September 10, 2013. The search wasperformed without any limitations of language. Review ar-
ticles, original articles, and other studies of interest were
examined to identify additional eligible studies.
Selection criteria
Studies included in the meta-analysis were required to
meet the following criteria: (1) studies investigating the
association between TNF-α gene polymorphisms and
prostate cancer risk; (2) case–control or cohort studies;
and (3) the papers must list the sample size, distribution
of genotype, and allele frequency. If serial studies of the
same population from the same group were reported,
the most recent or largest population was chosen. When
a study reported the results on different subpopulations,
we treated it as separate studies in the meta-analysis.
Studies were excluded from our meta-analysis if they
met one of the following exclusion criteria: (1) the study
was conducted on animals, (2) the design was based on
family or sibling pairs, or (3) insufficient original data
was available for data extraction, for instance, the num-
ber of genotypes could not be ascertained.
Data extraction
T Two separate investigators (Ma and Zhao) reviewed
and extracted data from the studies included indepen-
dently to ensure the accuracy of the data. The following
parameters were collected from eligible studies: first
author's surname, year of publication, country of study
population, ethnicity, genotyping methods, sample size,
source of controls (hospital-based, population-based, or
healthy volunteers), matching variables, prostate cancer
diagnosis, QC when genotyping, and the number of
genotype frequencies in cases and controls. The two in-
vestigators verified data accuracy by comparing collec-
tion forms between investigators. If different results
were generated, they would carry out discussions until a
consensus was reached.
Quality score assessment
The quality of the selected studies was independently
evaluated by two reviewers (Ma, and Zhao). The criteria
for quality appraisal are listed in Table 1. The quality
scoring system was originally proposed by Thakkinstian
et al. [18]. Scores ranged from the lowest value 0 to the
highest value 14, with higher scores indicating better
quality. Disagreements were resolved by consensus.
Statistical analysis
Crude odds ratios (ORs) and corresponding 95% confi-
dence intervals (CIs) were employed to estimate the
strength of association between the two polymorphisms
and prostate cancer risk. The recessive genetic model,
dominant genetic model and additive genetic models
were used to calculate the pooled ORs and 95% CIs for
Table 1 Scale for quality assessment
Criteria Score
1. Representativeness of cases
Selected from population or cancer registry 3
Selected from hospital 2
Selected from pathology archives, but without clearly defined
sampling frame or with extensive inclusion/exclusion criteria
1
Not described 0
2. Source of controls
Population- based 3
Blood donors or volunteers 2
Hospital-based (cancer -free patients) 1
Not described 0
3. Pecimens of cases determining genotypes
White blood cells or normal tissues 1
Tumor tissues or exfoliated cells of tissue 0
4. Ascertainment of prostate cancer
Histopathologic confirmation 2
Diagnosis of prostate cancer by patient medical record 1
Not described 0
5. Total sample size
≧1000 3
≧400 but <1000 2
≧200 but <400 1
<200 0
6. Hardy-Weinbe rg equilibrium in controls
Hardy-Wei nberg equilibrium 1
Hardy-Wei nberg disequilibrium 0
7. Quality control of genotyping methods
Repetition of partial/total tested samples 1
Not described 0 0
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dies included in the meta-analysis was evaluated by the
chi-square-based Q test and quantified by the I2 metric.
I2 values of 75%, 50%, and 25% were considered to re-
flect high, moderate, and low heterogeneity, respectively
[19]. When no statistical heterogeneity was found (I2 <
50% or P > 0.10), the ORs and 95% CI would be esti-
mated for each study in the fixed-effect model (Mantel-
Haenszel method) [20]. Otherwise, the random-effect
model (DerSimonian and Laird method) was applied
[21]. Logistic meta-regression and subgroup analyses
were performed to explore possible explanations for he-
terogeneity among studies. The following characteristics
of participants were included as covariates in the meta-
regression analysis: source of controls, ethnicity, geno-
typing methods, quality score, QC when genotyping, and
prostate cancer diagnosis. Subgroup analyses wereperformed by ethnic group and source of controls. In
addition, Galbraith plots analysis was performed for fur-
ther exploration of heterogeneity.
A funnel plot was used to verify potential publication
bias using the standard error of log (OR) for each publi-
cation plotted against its log (OR), and the asymmetry of
the funnel plot was tested by Egger’s regression [22].
The t test was used to determine the significance of the
asymmetry, and if the P value was <0.10, indicating the
presence of publication bias, the non-parametric “trim
and fill” method was used to adjust for it [23]. Sensitivity
analysis was conducted to validate the credibility of out-
comes in this meta-analysis. It was carried out by se-
quential omission of individual studies or by omitting
studies without high quality. The Hardy-Weinberg equi-
librium (HWE) in the controls was evaluated in our
meta-analysis using the goodness-of-fit chi-square test,
and p < 0.05 was considered representative of a depart-
ure from HWE. Statistical tests were performed using
the program STATA 12.0 software (Stata-Corp LP,
College Station, TX). All statistical tests were two-sided.
Results
Study characteristics
As shown in Figure 1, a total of 79 published records
found on Cochrane Library, PubMed, EMBASE, CBM,
and CNKI were identified as having met the search cri-
teria. After the titles and abstracts were reviewed, 66 of
these articles were excluded: 46 were not related to gene
polymorphisms, 17 articles discussed polymorphisms
other than –308G/A and/or –238G/A of TNF-α, 1 was
not closely relevant to prostate cancer, and 2 were meta-
analyses [17,24]. Manual search of references cited in
the published studies did not reveal any more relevant
articles. These 13 full-text articles were then subjected
to further examination, and 1 article was further ex-
cluded as it discussed the TNF-α gene and prognosis.
Thus, a total of 12 records with a case–control design
met the inclusion criteria for the meta-analysis (Figure 1).
Of these, two articles contained two different subpopula-
tions and were treated as two independent studies. The
corresponding characteristics are presented in Table 2.
Twelve articles [14-16,25-33] with 14 studies (5,757
cases and 6,137 controls) discussed TNF-α-308G/A
polymorphism, while 4 [15,16,30,31] articles containing
5 studies (1,967 cases and 2,004 controls) discussed
TNF-α-238G/A polymorphism. The number of cases in
these studies varied from 96 to 2,225, and the number of
controls varied from 126 to 2,251. Of all the eligible
studies for TNF-α-308G/A polymorphism, seven were
performed in Caucasians populations; four, in Asians;
two, in mixed populations (White and other); and one,
in an African-American population. Similarly for TNF-
α-238G/A polymorphism, three were performed in
79 records identified from database
after initial search up to September
10, 2013
0 Additional records identified
from retrieved articles
13 Potentially relevant records
included




12 Records including 14
studies for -308G/A
66 Records excluded (for title and
abstract)
38 records were not related gene
polymorphism
17 records were polymorphism other than -
308G/A and/ or -238G/A of TNF-α
1 record was not closely relevant to
prostate cancer
10 records were reviews or meta-analysis
1 Record excluded
1 concerning the TNF-α gene and
prognosis
4 Records including 5 studies
for -238G/A
Figure 1 Flow diagram of included studies for this meta-analysis.
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performed using polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP), amplification
refractory mutation system-PCR (ARMS-PCR), TaqMan
assay, and polymerase chain reaction (PCR) analyses on
genomic DNA. For the TNF-α-308G/A polymorphism, the
genotype distributions in the control groups of all but one
study were in agreement with the HWE [33]. Similarly, for
the TNF-α-238G/A polymorphism, the genotype distribu-
tions in the control group of one study [30] was not con-
sistent with the HWE.
Results of the meta-analysis
The data suggested no significant association between the
TNF-α-308G/A polymorphism and prostate cancer risk in
all genetic models (additive genetic models: AA vs. GG
and AG vs. GG, recessive genetic model: AA vs. AG+GG,
and dominant genetic model: AA +AG vs. GG; Table 3,
Figure 2) in the overall populations. Additional subgroup
analyses stratified by ethnicity revealed no association be-
tween TNF-α-308G/A polymorphism and prostate cancer
risk in any of the genetic models. When stratified by
source of controls, a significantly increased prostate can-
cer risk was found among healthy volunteer studies in the
additive model AG vs. GG (OR = 1.477, 95% CI = 1.047–
2.085, P = 0.026, I2 = 0.0%, and PQ = 0.602 for heterogen-
eity) and dominant model AA +AG vs. GG (OR = 1.531,
95% CI = 1.093–2.145, P = 0.013, I2 = 0.0%, and PQ = 0.628
for heterogeneity) but not in the recessive model AA vs.
AG +GG (OR = 2.65, 95% CI = 0.679–10.341, P = 0.161,I2 = 0.0%, and PQ = 0.997 for heterogeneity). Furthermore,
excluding the studies by OH et al. [16] and Sáenz-López
et al. [14], which were shown as outliers in our Galbraith
plot analysis, did not influence the significance of the
summary ORs for the TNF-α-308G/A polymorphism in
different comparison models in the overall population and
subgroup analyses.
Data from five case–control studies comprising 1,967
prostate cancer cases and 2,004 controls were pooled for
the analysis of the TNF-α-238G/A polymorphism. No asso-
ciation was detected between TNF-α-238G/A polymorph-
ism and prostate cancer risk in all genetic models in the
overall population. Similarly, in the subgroup analysis by
source of controls and ethnicity, no significant association
was found (Table 3).Heterogeneity analysis
For the TNF-a-308G/A polymorphism, substantial he-
terogeneities between studies were observed in the additive
and dominant models (p < 0.001 in both models) in the
overall populations. We further employed meta-regression
and subgroup analyses to explore the source of heterogen-
eity. However, meta-regression analysis of data showed that
ethnicity, genotyping methods, source of controls, QC
when genotyping, prostatic cancer diagnosis, and quality
scores did not affect modifiers. Subsequently, we stratified
the studies by ethnicity and source of controls, and ob-
served the lack of homogeneity among Caucasians and
hospital-based studies in the two genetic models (Table 3).
Table 2 Characteristics of eligible studies in this meta-analysis












PI HWE (P value) Quality
scores
−308G/A −238G/A
Ribeiro (2012) Portugal Caucasia TaqMan HB 449/557 Age HC No −308G/A 0.155 - 10
Berhane (2012) India (N) Asia ARMS-PCR HB 150/150 Age HC No −308G/A 0.662 - 10
Wang (2009) America (W) mixed TaqMan PB 251/250 Age, sex,ethnicity HC No −308G/A 0.529 - 12
Moore (2009) Finland (W) mixed TaqMan PB 949/857 Age, sex HC Yes −308G/A 0.231 - 14
Kesarwani (2009) India (E) Asia PCR-RFLP PB 197/256 Age, sex, ethnicity HC Yes −308G/A 0.115 - 13
Zabaleta 1 (2008) America (W) Caucasia TaqMan HB 950/785 Ethnicity HC Yes −308G/A,-238G/A 0.505 0.295 10
Zabaleta 2 (2008) America (W) African-American TaqMan HB 131/256 Ethnicity HC Yes −308G/A,-239G/A 0.959 0.006 8
Sáenz-López (2008) Spain Caucasia TaqMa HV 296/310 Ethnicity HC No −308G/A 0.715 - 9
Danforth 1 (2008) America (W) Caucasia TaqMan PB 1155/1389 Age HC Yes −308G/A 0.795 - 14
Danforth 2 (2008) America (W) Caucasia TaqMan PB 2225/2251 Age HC Yes −308G/A,-239G/A 0.217 0.737 14
Ge (2007) China Asia TaqMan HB 490/490 Age HC + PC No −308G/A 0.609 0.462 11
Wu (2004) China Asia PCR HV 96/126 Sex HC No −308G/A,-239G/A 0.883 - 7
McCarron (2002) UK Caucasia PCR HB 239/220 Ethnicity HC No −308G/A 0.023 - 7
OH (2000) America Caucasia PCR HB 146/244 Ethnicity PC Yes −308G/A,-239G/A 0.554 0.091 9
PI, Polymorphism(s) investigated; QC, Quality control; NA, Not available; PB, Population–based; HB, Hospital–based; HV, healthy-volunteers; HC, Histologically confirmed; PC, Pathologically confirmed; HWE, Hardy–Weinberg
















Table 3 Meta-analysis of the TNF-α gene polymorphisms on prostate cancer risk
Comparison Population No. of studies Test of association Test of heterogeneity
OR 95% CI P value model X2 I2(%) P value
TNF-α-308G/A
AA vs. GG Overall 14 0.936 0.733-1.195 0.595 F 16.20 19.8 0.238
Caucasia 8 0.762 0.569-1.021 0.068 F 5.68 0.0 0.461
Asia 3 1.558 0.620-3.419 0.346 F 4.29 30.1 0.231
Mix 2 1.616 0.917-2.848 0.097 F 0.11 0.0 0.736
African-American 1 1.119 0.181-6.903 0.904 - - - -
PB 5 0.886 0.660-1.190 0.422 F 6.72 40.5 0.152
HB 7 0.924 0.557-1.481 0.743 F 6.76 11.2 0.344
HV 2 2.861 0.732-11.181 0.131 F 0.00 0.0 0.979
AG vs. GG Overall 14 1.105 0.932-1.309 0.251 R 41.38 68.6 <0.001
Caucasia 7 1.234 0.965-1.600 0.092 R 31.63 81.0 <0.001
Asia 4 0.928 0.699-1.234 0.608 F 4.12 27.2 0.249
Mix 2 1.065 0.882-1.288 0.512 F 0.70 0.0 0.404
African-American 1 0.458 0.204-1.027 0.058 - - - -
PB 5 0.997 0.899-1.106 0.958 F 3.39 0.0 0.495
HB 7 1.174 0.709-1.746 0.428 R 32.78 81.7 <0.001
HV 2 1.477 1.047-2.085 0.026 F 0.27 0.0 0.602
AA + AG vs. GG Overall 14 1.103 0.932-1.306 0.254 R 43.71 70.3 <0.001
Caucasia 8 1.206 0.941-1.545 0.138 R 32.21 81.4 <0.001
Asia 3 1.008 0.657-1.547 0.97 R 6.83 56.1 0.078
Mix 2 1.101 0.916-1.323 0.304 F 0.63 0.0 0.429
African-American 1 0.513 0.242-1.088 0.082 - - - -
PB 5 0.987 0.892-1.091 0.799 F 4.96 19.4 0.291
HB 7 1.174 0.803-1.719 0.408 R 32.22 81.4 <0.001
HV 2 1.531 1.093-2.145 0.013 F 0.24 0.0 0.628
AA vs. GG + AG Overall 14 0.92 0.721-1.172 0.502 F 16.2 19.7 0.239
Caucasia 7 0.748 0.559-1.001 0.051 F 5.93 0.0 0.431
Asia 4 1.559 0.618-3.935 0.347 F 3.98 24.7 0.263
Mix 2 1.569 0.893-2.757 0.117 F 0.19 0.0 0.660
African-American 1 1.303 0.212-7.991 0.775 - - - -
PB 5 0.883 0.659-1.184 0.407 F 6.26 36.1 0.181
HB 7 0.886 0.555-1.413 0.611 F 7.49 19.9 0.278
HV 2 2.65 0.679-10.341 0.161 F 0.00 0.0 0.997
TNF-α-238G/A
AA vs. GG Overall 4 1.09 0.403-2.943 0.866 F 4.61 34.9 0.203
Caucasia 3 1.29 0.436-3.816 0.645 F 4.35 54.1 0.113
African-American 1 0.391 0.018-8.288 0.547 - - - -
HB 3 1.579 0.492-5.071 0.442 F 3.750 46.7 0.153
PB 1 0.344 0.036-3.310 0.355 - - - -
AG vs. GG Overall 5 1.07 0.680-1.683 0.77 R 12.49 68.0 0.014
Caucasia 3 1.284 0.841-2.025 0.282 R 5.99 66.6 0.050
Asia 1 0.431 0.200-0.931 0.032 - - - -
African-American 1 1.179 0.408-3.405 0.706 - - - -
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Table 3 Meta-analysis of the TNF-α gene polymorphisms on prostate cancer risk (Continued)
HB 4 1.008 0.506-2.010 0.981 R 11.3 73.4 0.01
PB 1 1.248 0.944-1.649 0.12 - - - -
AA + AG vs. GG Overall 5 1.06 0.713-1.575 0.774 R 9.95 59.8 0.041
Caucasia 3 1.226 0.982-1.531 0.072 F 3.33 39.9 0.189
Asia 1 0.431 0.200-0.931 0.032 - - - -
African-American 1 0.983 0.351-2.752 0.974 - - - -
HB 4 0.984 0.535-1.808 0.958 R 9.170 67.3 0.027
PB 1 1.221 0.926-1.610 0.156 - - - -
AA vs. GG + AG Overall 4 1.036 0.388-2.767 0.943 F 4.9 38.2 0.182
Caucasia 3 0.892 0.084-9.494 0.925 R 4.63 56.8 0.099
African-American 1 0.386 0.018-8.161 0.541 - - - -
HB 3 1.468 0.467-4.615 0.511 F 4.050 50.6 0.132
PB 1 0.336 0.035-3.238 0.346 - - - -
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factors for heterogeneity.
We also performed Galbraith plots analysis to identify
the outliers that might contribute to the heterogeneity.
The study of Oh et al. [16] was an outlier in the additive
model AG vs. GG, while the studies of Oh et al. [16] and
Sáenz-López et al. [14] were both outliers in the domin-
ant model AA + AG vs. GG for TNF-α-308G/A poly-
morphism (Figure 3). When these two studies were
excluded from the analysis, the I2 values decreased obvi-
ously and the PQ values were greater than 0.10 in the
overall populations (additive model: PQ = 0.267, I
2 =
17.5%; dominant model: PQ = 0.295, I
2 = 15.2%), Cauca-
sians (additive model: PQ = 0.379, I
2 = 5.9%; dominant
model: PQ = 0.883, I
2 = 0.0%), and hospital-based studies
(additive model: PQ = 0.294, I
2 = 18.4%; dominant model:
PQ = 0.240, I
2 = 25.9%).
For the TNF-α-238G/A polymorphism, substantial
heterogeneities were observed between studies in theFigure 2 Forest plots of TNF-α gene polymorphisms and prostate can
cancer risk (AA + AG vs. GG), b Forest plots of TNF-α-238G/A polymorphismadditive model AG vs. GG (p = 0.014) and dominant
model AA + AG vs. GG (p = 0.041) in the overall popula-
tions. We further employed subgroup analyses stratified
by ethnicity and source of controls. However, hetero-
geneities were still observed among hospital-based stud-
ies in these two genetic models (Table 3). Therefore,
ethnicity was considered to contribute to substantial het-
erogeneity.
Sensitivity analysis
A leave-one-out sensitivity analysis was performed to re-
flect the influence of the individual dataset to the pooled
ORs. The results suggested that no single investigation
significantly affected the pooled ORs (data not shown).
When we excluded HWE-violating studies, the corre-
sponding pooled ORs were not materially altered, indicat-
ing that the data in this meta-analysis are relatively stable
and credible.cer risk. a Forest plots of TNF-α-308G/A polymorphism and prostate
and prostate cancer risk (AA + AG vs. GG).
Figure 3 Galbraith plots of TNF-α-308G/A polymorphism and prostate cancer risk in different contrast models. a The studies of OH et al.,
Sáenz-López et al. were outliers in dominant models AA + AG vs. GG. b OH et al. was outlier in additive model AG vs. GG.
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Begg’s funnel plot and Egger's linear regression tests were
created to estimate the publication bias risk in this meta-
analysis. As shown in Figure 4, the shapes of the funnel
plots did not show obvious asymmetry. In addition, the re-
sults of Egger’s test also revealed the absence of publica-
tion bias in the TNF-α-308G/A (P = 0.224 for AA vs. GG;
P = 0.350 for AG vs. GG; P = 0.313 for recessive model AA
vs. GG+AG; and P = 0.275 for dominant model AA+AG
vs. GG) and TNF-α-238G/A (P = 0.742 for AA vs. GG;
P = 0.758 for AG vs. GG; P = 0.763 for recessive model AA
vs. GG+AG; and P = 0.629 for dominant model AA+AG
vs. GG) polymorphisms.
Discussion
TNF-α is a member of the TNF/TNFR cytokine superfam-
ily, and is an intercellular communicating molecule in-
volved in building transient or long-lasting multicellular
structures [34]. It is also known to play critical and non-
redundant roles in the innate and adaptive immune re-
sponses [35], including the response to tumours [36]. TNF-Figure 4 Funnel plot for the detection of the publication bias in this
308G/A polymorphism in overall analysis; b Funnel plot for contrast AA + Aα has been directly and indirectly linked to neoplasia and is
involved not only in maintenance and homeostasis of the
immune system, inflammation, and host defence, but also
in pathological processes such as chronic inflammation,
autoimmunity, and malignant disease [35,37]. TNF-α ex-
pression is mostly regulated at the transcriptional level [38].
Promoter polymorphisms in the TNF-α gene related to the
pro- and anti-inflammatory response could directly influ-
ence production of TNF-α, thus causing inter-individual
differences in immune responsiveness, which may influence
the susceptibility of prostate cancer [39].
Two variations in the promoter region of the TNF-α
gene, namely, TNF-α-308G/A and TNF-α-238G/A, have
been commonly studied. The G to A substitution at
position −308 in the TNF-a promoter increases TNF-α
transcription activity and the serum TNF-α level [6].
Indeed, the TNF-308A allele has been associated with ma-
lignant tumours such as gastric cancer, breast carcinoma,
and hepatocellular cancer [40-42]. The functional signifi-
cance of the rare TNF-238A allele is not yet clear, but
Kaluza et al. reported that this allele caused a significantmeta-analysis. a Funnel plot for contrast AA + AG vs. GG of TNF-α-
G vs. GG of TNF-α-238G/A polymorphism in overall analysis.
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T and B cells [43]. The allele has also been associated with
certain autoimmune and infectious diseases [44,45]. Several
studies have observed the association between prostate can-
cer risk and TNF-α promoter polymorphisms, and TNF-α-
308G/A and/or TNF-α-238G/A polymorphisms, but the
results are controversial. These inconsistent results are
possibly because of the small effect of the polymorphism
on prostate cancer risk or the relatively low statistical
power of the published studies. Meta-analysis could over-
come these disadvantages because (1) it can investigate data
for a large number of individuals; (2) it can estimate the
effect of a genetic factor on disease risk; and (3) if a signifi-
cant association is found, it can estimate whether the asso-
ciation is common among different backgrounds (such as
population or age groups) [46-49]. Therefore, we performed
a meta-analysis to comprehensively evaluate the associ-
ation between TNF-α-308G/A and/or TNF-α-238G/A
polymorphisms and prostate cancer risk.
Our meta-analysis summarized for the first time all
the available data on the association between TNF-α-
238G/A polymorphism and prostate cancer risk, inclu-
ding a total of five studies, involving 1,967 prostate
cancer cases and 2,004 controls. Our results demon-
strated that the TNF-α-238G/A polymorphism was not
significantly associated with prostate cancer risk not
only in the overall population but also in the subgroup
analyses stratified by ethnicity and source of controls.
With respect to TNF-α-308G/A polymorphism, 14
studies including 5,757 prostate cancer cases and 6,137
controls were found in our meta-analysis. The data sug-
gested no significant association between TNF-α-308G/A
polymorphism and prostate cancer risk in all genetic
models in the overall populations, which is consistent with
the previous findings made by Wang et al. [24] and Wang
et al. [17]. However, in the subgroup analysis according to
source of controls, significantly increased prostate cancer
risk was found in the healthy volunteer studies but not in
hospital-based and population-based studies. However,
the result may be underpowered because the sample size
the healthy volunteer studies in this analysis is relatively
small, and controls in these studies may not always be
truly representative of the general population. Therefore, a
methodologically preferable design such as a representa-
tive population-based study is needed to avoid selection
bias and to increase the statistical power.
For the TNF-α-308G/A polymorphism, substantial het-
erogeneities between studies were observed in the additive
model AG vs. GG (p < 0.001) and dominant model AA +
AG vs. GG (p < 0.001) in the overall populations. To
explore the source of heterogeneity, we employed meta-
regression and subgroup analyses. Meta-regression analysis
revealed no definite source of heterogeneity. Subgroup
analyses by ethnicity showed that heterogeneity existed inCaucasian subjects and hospital-based studies in the
additive and dominant models. To further investigate the
heterogeneity, Galbraith plot analysis was used to identify
the outliers that might contribute to the heterogeneity, and
two outliers were found. When they were excluded from
the analysis, the I2 values decreased obviously and PQ
values were greater than 0.10 in the overall populations and
in Caucasians. In addition, excluding the two studies did
not significantly affect the results in the different compari-
son models in the overall population and subgroup ana-
lyses. The results indicated that the two studies might be
the major source of the heterogeneity for the 308G/A
polymorphism.
Substantial heterogeneities between studies were ob-
served in the additive and dominant models for the TNF-
α-238G/A polymorphism in the Caucasian population
and hospital-based studies. As only five studies on the
association between TNF-α-238G/A polymorphism and
prostate cancer risk were included in our meta-analysis,
meta-regression analysis and Galbraith plots analysis were
not performed; therefore, these results require further
investigation.
This meta-analysis has some limitations that must be
considered. First, the overall outcomes were based on indi-
vidual unadjusted ORs, while a more precise estimation
should be adjusted by confounding factors such as smoking
status, age, and environmental factors. Second, the sample
sizes in this analysis were not adequate, especially the
African-American populations; therefore, more subjects of
different ethnicities would be required to accurately clarify
whether ethnicity has a biological influence on cancer
susceptibility. Third, the controls were not consistently
screened across the studies analysed. Therefore, the control
groups may have different risks of developing prostate can-
cer. Fourth, as only certain published studies were included
in our meta-analysis, publication bias is very likely to occur
although it was not shown in the statistical test.
Conclusions
In conclusion, the present meta-analysis suggests that the
TNF-α-238/A polymorphism is unlikely to be a risk factor
for prostate cancer, while the TNF-α-308 G/A polymorph-
ism may make a significant contribution to the risk of pros-
tate cancer in healthy volunteers. However, to clarify the
role of TNF-α-308G/A and TNF-α-238G/A polymorphism
in prostate carcinogenesis, more studies with large samples
are needed in the future.
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